Fulcrum Therapeutics Joins in Effort to “Reframe Rare” to Commemorate Rare Disease Day 2020
February 28, 2020 07:00 ET
|
Fulcrum Therapeutics
CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
December 02, 2019 10:37 ET
|
Fulcrum Therapeutics
CAMBRIDGE, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights
November 14, 2019 07:00 ET
|
Fulcrum Therapeutics
– Announced preliminary results of a Phase 1 clinical trial of losmapimod in FSHD patients – – Initiated IND-enabling studies for FTX-6058 for the potential treatment of sickle cell disease and...
Fulcrum Therapeutics to Present at the Stifel 2019 Healthcare Conference
November 13, 2019 08:01 ET
|
Fulcrum Therapeutics
CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019
November 06, 2019 08:01 ET
|
Fulcrum Therapeutics
CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics to Host Key Opinion Leader Breakfast Symposium on Facioscapulohumeral Dystrophy (FSHD), on November 7, 2019
October 31, 2019 08:00 ET
|
Fulcrum Therapeutics
CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics Announced Results of Phase 1 Clinical Trial of Losmapimod in FSHD
October 04, 2019 04:30 ET
|
Fulcrum Therapeutics
CAMBRIDGE, Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Announces Multiple Presentations of Losmapimod Data at World Muscle Society Meeting
October 01, 2019 07:00 ET
|
Fulcrum Therapeutics
Oral presentation to highlight Phase 1 data on safety, tolerability and target engagement of losmapimod in treatment of FSHDCompany also announces updated preclinical data on FTX-6058 for potential...
Fulcrum Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
September 03, 2019 16:01 ET
|
Fulcrum Therapeutics
CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights
August 26, 2019 07:00 ET
|
Fulcrum Therapeutics
– Completed initial public offering, raising $72.0 million in gross proceeds – – Initiated ReDUX4, a Phase 2b clinical trial of losmapimod in FSHD – – Initiated a Phase 2 open label clinical trial...